Everest Medicines Limited, incorporated in the Cayman Islands and listed under Stock Code 1952, has announced the completion of a placing of existing shares and a top-up subscription of new shares under a general mandate. The company successfully placed an aggregate of 22,561,000 sale shares through placement agents, on a best effort basis, to not less than six placees, at a purchase price of HK$69.70 per sale share. This strategic move is part of the company's efforts to optimize its capital structure and support its ongoing business initiatives. Everest Medicines' Board, led by Chairman and Executive Director Wei Fu, expressed satisfaction with the successful completion of the transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.